跳至主要内容
临床试验/ISRCTN24452099
ISRCTN24452099招募中不适用

Perspective study on an effective treatment for acute myeloid leukemia with decitabine and chemotherapy

Heilongjiang Institute for Hematology and Oncology Research (China)0 个研究点目标入组 3,000 人开始时间: 2014年10月23日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
3,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Any age AML patients (except APL) at different treatment stages, who are responsive or non-responsive to conventional treatments are all included in this trial
  • 2. Patients agreed to receive the treatment

排除标准

  • 1. Previous history of severe cardiovascular disease (coronary arterial disease, stroke, etc.)
  • 2. Severe chronic disease with poor prognosis (liver disease, kidney disease, etc.)
  • 3. Illegal drug use or chronic alcoholism
  • 4. Physical limitations, mental or intellectual disabilities
  • 5. Any condition that may affect the development of this trial

研究者

发起方
Heilongjiang Institute for Hematology and Oncology Research (China)

相似试验

To evaluate chemotherapy and decitabine treatment... | 临床试验